Carcinoid Syndrome

Treat abrupt flushing, bronchospasm, severe diarrhea, or hemodynamic instability during tumor manipulation, anesthesia, or other physiologic stress as possible carcinoid crisis. Crisis is more likely in patients with liver metastases and can be life-threatening. journal chestnetjournal chestnetADULT MALE DEVELOPS CARCINOID CRISIS ON ... Coordinate urgent anesthesia, oncology, and surgical management; intravenous octreotide has been used intraoperatively for hypotensive crisis, including 500 to 1,000 mcg boluses repeated at 5-minute intervals until symptom control in a pediatric drug monograph. publications aappublications aapOctreotide | Drug Lookup | Pediatric Care Online

Assess for carcinoid heart disease at presentation of clinically established carcinoid syndrome and before operative interventions. Obtain transthoracic echocardiography to identify valvular dysfunction or heart failure; this is specifically recommended preoperatively when carcinoid syndrome is present. ASCO+1ASCOSymptom Management for Well-Differentiated ...PubMedGastrointestinal Neuroendocrine Tumors - StatPearls - NCBI Bookshelf Escalate promptly to a multidisciplinary heart-valve and neuroendocrine tumor team when echocardiography identifies clinically consequential valvular disease, because valve replacement may be complicated by persistent hormonal activity, hepatic dysfunction, and right-sided heart failure. jtcvsjtcvsImproving outcome of valve replacement for carcinoid heart ...

Do not attribute edema, ascites, fatigue, or exertional limitation solely to hepatic tumor burden or diarrhea-related volume loss. In advanced small-intestinal neuroendocrine tumors with carcinoid syndrome, carcinoid heart disease develops in up to 50% of patients. ScienceDirectScienceDirectCarcinoid heart disease in patients with advanced small ...

In patients with a compatible pattern of recurrent flushing, secretory diarrhea, bronchospasm, or suspected hormone-mediated right-sided valvular disease, measure urinary 5-HIAA as the principal biochemical test for carcinoid syndrome. Urinary 5-HIAA testing supports the diagnosis, while imaging is used to localize and stage the underlying neuroendocrine tumor. PubMedPubMedCarcinoid Syndrome - StatPearls - NCBI Bookshelf

Interpret a positive biochemical and clinical syndrome in the context of tumor distribution. Carcinoid syndrome is most commonly associated with metastatic, well-differentiated midgut neuroendocrine tumors, especially when liver metastases allow serotonin and other tumor mediators to reach the systemic circulation. ScienceDirect+1ScienceDirectTelotristat - an overview | ScienceDirect TopicsPubMedCarcinoid Syndrome - StatPearls - NCBI Bookshelf Small-intestinal neuroendocrine tumors frequently metastasize to the liver, and approximately 30% may present with carcinoid syndrome. ScienceDirectScienceDirectCarcinoid syndrome and neuroendocrine tumours

Establish whether the malignancy is a well-differentiated gastrointestinal neuroendocrine tumor or a poorly differentiated high-grade neuroendocrine carcinoma. This distinction changes systemic treatment direction: somatostatin analog–based approaches are central for functioning well-differentiated disease, whereas platinum-etoposide chemotherapy is described as the mainstay for high-grade or metastatic neuroendocrine carcinomas. PubMedPubMedNothing But NET: A Review of Neuroendocrine Tumors and Carcinomas Pathology review is therefore necessary whenever morphology, grade, clinical tempo, or treatment response raises concern for high-grade disease.

Initiate a long-acting somatostatin analog for symptomatic carcinoid syndrome. Available long-acting agents are octreotide LAR, given intramuscularly every 4 weeks, and lanreotide, given by deep subcutaneous injection every 4 weeks. Both have antisecretory and antiproliferative evidence in midgut neuroendocrine tumors and similar somatostatin receptor subtype-binding profiles, particularly affinity for SSTR2. PubMedPubMedThe North American Neuroendocrine Society (NANETS) Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

For initial or nonrefractory carcinoid syndrome, consensus guidance lists octreotide LAR 20 to 30 mg intramuscularly as an available U.S. option; immediate-release octreotide can be used for breakthrough symptoms. PubMedPubMedConsensus Guidelines for the Management and Treatment of Neuroendocrine Tumors - PMC The treatment target is reduction of flushing and diarrhea while the oncology team concurrently evaluates disease burden and radiographic trajectory.

Continue somatostatin analog therapy in functioning carcinoid syndrome when additional tumor-directed therapy is introduced. Long-term therapy is described as lifelong for carcinoid syndrome and other responsive functioning syndromes, including after radiologic or clinical progression, although continuation after progression in nonfunctioning gastrointestinal NET remains controversial. PubMedPubMedGastrointestinal Neuroendocrine Tumors and the Carcinoid Syndrome - Endotext - NCBI Bookshelf This distinction matters: persistent hormone secretion remains a clinical indication for ongoing antisecretory treatment even when a second-line antitumor therapy is added. PubMedPubMedGastrointestinal Neuroendocrine Tumors and the Carcinoid Syndrome - Endotext - NCBI Bookshelf

For refractory carcinoid syndrome with stable tumor volume, consensus guidance supports antidiarrheal agents and recommends considering dose escalation or shortening the dosing interval of the long-acting somatostatin analog; however, prospective randomized evidence for somatostatin analog dose or interval escalation is lacking. PubMedPubMedConsensus Guidelines for the Management and Treatment of Neuroendocrine Tumors - PMC A symptom pattern that worsens near the end of the dosing cycle favors an administration-interval strategy, whereas worsening symptoms with radiographic progression favors tumor-directed escalation.

Add telotristat ethyl for persistent carcinoid-syndrome diarrhea in patients already receiving somatostatin analog therapy. In placebo-controlled phase 3 studies, telotristat 250 mg three times daily reduced urinary 5-HIAA, and PRRT with 177Lu-DOTATATE has also reduced diarrhea and flushing in carcinoid syndrome. Oxford Academic+1Oxford AcademicPeptide Receptor Radionuclide Therapy With 177 Lu ...ema europa euXermelo 250 mg film-coated tablets Telotristat should be taken with food; the cited product information advises reducing to 250 mg twice daily as tolerated in Child-Pugh A impairment, 250 mg once daily as tolerated in Child-Pugh B impairment, and avoiding use in Child-Pugh C impairment. ema europa euema europa euXermelo 250 mg film-coated tablets

When liver metastases are unresectable and symptom control remains suboptimal on somatostatin analog therapy, hepatic arterial embolization is an appropriate palliative option by NANETS consensus and is associated with high rates of symptom improvement in reported series of hormonal syndromes. PubMedPubMedThe North American Neuroendocrine Society (NANETS) Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors In the same clinical setting, systemic options such as PRRT or everolimus may be added to somatostatin analogs, but comparative evidence for symptom control across these approaches remains limited. PubMedPubMedThe North American Neuroendocrine Society (NANETS) Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors

For somatostatin receptor-positive advanced NET with persistent tumor growth or hormone-related symptoms, PRRT is a tumor-directed option; 177Lu-DOTATATE has demonstrated reduction in flushing and diarrhea in patients with carcinoid syndrome. ScienceDirect+1ScienceDirectEdotreotide - an overview | ScienceDirect TopicsOxford AcademicPeptide Receptor Radionuclide Therapy With 177 Lu ... Select the modality with the multidisciplinary NET team according to somatostatin receptor status, extent and distribution of disease, liver-directed therapy feasibility, prior treatments, and cardiac reserve.

At each treatment review, document bowel-movement burden, flushing frequency, breakthrough symptoms, somatostatin analog injection timing, and adverse effects. Use urinary 5-HIAA as a biochemical marker of serotonin activity and repeat imaging to assess localization, staging, and tumor trajectory when symptoms change or tumor-directed treatment decisions are being made. PubMed+1PubMedCarcinoid Syndrome - StatPearls - NCBI Bookshelfema europa euXermelo 250 mg film-coated tablets

Maintain a low threshold to repeat transthoracic echocardiography when symptoms or signs suggest evolving valvular dysfunction or right-sided heart failure. Carcinoid heart disease is a systemic complication of serotonin-secreting disease and is particularly relevant in advanced small-intestinal NET with carcinoid syndrome. ScienceDirect+1ScienceDirectCarcinoid heart disease in patients with advanced small ...PubMedCarcinoid Syndrome - StatPearls - NCBI Bookshelf Valve intervention requires coordinated assessment because active carcinoid syndrome, hepatic dysfunction, and right-heart failure complicate replacement procedures. jtcvsjtcvsImproving outcome of valve replacement for carcinoid heart ...

For patients undergoing abdominal surgery who are expected to receive long-term somatostatin analog therapy, consider prophylactic cholecystectomy at the time of surgery because prolonged somatostatin analog exposure increases biliary complications such as cholelithiasis and cholecystitis. PubMedPubMedGastrointestinal Neuroendocrine Tumors - StatPearls - NCBI Bookshelf This is a procedural opportunity decision rather than an indication for stand-alone cholecystectomy in every patient.